Business
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
About this update from Ginkgo Bioworks Holdings, Inc.
[{"type":"text","content":"Ginkgo provides an update on its fourth quarter financial results","length":65,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.","length":384,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Ginkgo Bioworks)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Ginkgo Bioworks)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/fe3c2abd5acfb0739db965e53a5bec87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pD7D8Jpi1nYhM2EkNRaAzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fe3c2abd5acfb0739db965e53a5bec87","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1583909/Ginkgo_Logo_Lockup.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Fourth Quarter 2025 Financial Results","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year period, Total revenue in the fourth quarter of 2025 decreased 24% from the comparable prior year period.","length":206,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter 2025 Cell Engineering revenue of $26 million compared to $35 million in the comparable prior year period, a decrease of 26%","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth quarter 2025 Biosecurity revenue of $7 million compared to $9 million in the comparable prior year period","length":117,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":255,"olType":false}]},{"val":[{"type":"text","content":"Fourth quarter 2025 GAAP net loss of $(81) million, compared to $(108) million in the comparable prior year period","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth quarter 2025 Adjusted EBITDA of $(36) million, up from $(57) million in the comparable prior year ...